Navigation Links
BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens

BALTIMORE, March 28, 2011 /PRNewswire/ -- Clinicians now have a new tool to help diagnose symptomatic patients with Herpes Simplex Viruses (HSV1 and HSV2) -- one of the most common sexually transmitted infections in the world.  

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the first fully automated molecular tests to detect and differentiate HSV types 1 and 2 in clinician-collected external anogenital specimens.  

The new BD ProbeTec™ Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays (HSV Qx Assays) run on the BD Viper™ System with XTR™ Technology, which uses Strand Displacement Amplification technology to qualitatively detect and differentiate HSV1 and HSV2 DNA.

"HSV is a highly infectious virus that many patients do not even realize they have," said Edward W. Hook III, Director of Infectious Disease, University of Alabama at Birmingham Department of Medicine.  "Advances in molecular testing are enhancing our ability to identify these patients rapidly and accurately in order to treat them more effectively and minimize their risk of spreading it to others."

"Identifying HSV patients and determining whether they have a type 1 or 2 infection is critical to treating them effectively and preventing further spread of the disease," said Wayne Brinster, Vice President and General Manager, Women's Health and Cancer, BD Diagnostics.  "Our new HSV tests are part of a growing portfolio of molecular diagnostics that is designed to give clinicians better tools to manage patients who may be suffering from a variety of the most pressing sexually transmitted infections."

The new BD ProbeTec HSV Qx Assays offer excellent sensitivity and specificity and a significant improvement in the time-to-results over culture methods, which often take 2-10 days for results.  BD's new automated HSV assays also provide laboratories with the capability to read up to 96 positive or negative results in about two and a half hours.  Using the BD Viper System with XTR Technology, laboratories also will be able to test other samples for chlamydia and gonorrhea on the same automated run used for the BD ProbeTec HSV1 and HSV2 Qx Assays.  

The assays are not FDA cleared for use with cerebrospinal fluid (CSF) or any lesions other than anogenital lesions.  The assays are not intended to be used for prenatal screening or for individuals under the age of 17 years.

For more information on the BD Viper System with XTR Technology and the BD ProbeTec Qx Amplified DNA Assays, please visit:

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit


Jeff Ezell
BD Public Relations
(201) 847-5533

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
2. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
3. Exosome Diagnostics Announces Additions to Management Team
4. Pathwork Diagnostics Closes $20M Financing
5. Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.
6. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
7. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
8. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
9. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
10. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
11. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
Breaking Biology News(10 mins):